| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A Colao, P Marzullo, S Spiezia, D Ferone, A Giaccio, G Cerbone, R Pivonello, C Di Somma, G Lombard. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. The Journal of clinical endocrinology and metabolism. vol 84. issue 6. 1999-07-02. PMID:10372698. |
effect of growth hormone (gh) and insulin-like growth factor i on prostate diseases: an ultrasonographic and endocrine study in acromegaly, gh deficiency, and healthy subjects. |
1999-07-02 |
2023-08-12 |
human |
| A Colao, P Marzullo, S Spiezia, D Ferone, A Giaccio, G Cerbone, R Pivonello, C Di Somma, G Lombard. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. The Journal of clinical endocrinology and metabolism. vol 84. issue 6. 1999-07-02. PMID:10372698. |
to assess the effect of gh and igf-i levels on prostate pathophysiology, 46 acromegalic (30 in active disease, 10 cured from acromegaly, and 6 affected from gh deficiency) and 30 age-matched male controls, free from previous or concomitant prostate disorders, underwent pituitary, androgen, and prostate hormonal assessments and transrectal ultrasonography. |
1999-07-02 |
2023-08-12 |
human |
| P Dasgupta, A T Singh, R Mukherje. Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin. Biochemical and biophysical research communications. vol 259. issue 2. 1999-06-28. PMID:10362518. |
such potent gh-inhibitory chimeric peptides may be of potential importance in the therapy of acromegaly, as well as provide novel tools to study the regulation of gh secretion by ghrp and somatostatin. |
1999-06-28 |
2023-08-12 |
rat |
| C B Newma. Medical therapy for acromegaly. Endocrinology and metabolism clinics of North America. vol 28. issue 1. 1999-06-10. PMID:10207690. |
evidence in the literature supports the use of these medications as secondary therapy in patients with acromegaly who have had surgery and who continue to have elevated gh levels (above 2 ng/ml during an oral glucose tolerance test) with or without igf-1 concentrations that are above the upper limit of normal for age. |
1999-06-10 |
2023-08-12 |
Not clear |
| J Hradec, J Kral, T Janota, M Krsek, V Hana, J Marek, M Mali. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). The American journal of cardiology. vol 83. issue 10. 1999-06-08. PMID:10335774. |
this documents a regression of left ventricular hypertrophy in acromegaly after lanreotide treatment, the degree of which is dependent on the magnitude of the decrease of gh and insulin-like growth factor-1 serum levels. |
1999-06-08 |
2023-08-12 |
Not clear |
| H S Chen, H D Li. Serum IGF-I and IGFBP-3 levels for the assessment of disease activity of acromegaly. Journal of endocrinological investigation. vol 22. issue 2. 1999-06-07. PMID:10195375. |
to assess the disease activity of acromegaly in patients, we measured the changes in serum growth hormone (gh) levels during oral glucose tolerance test and the basal serum levels of insulin-like growth factor i (igf-i) and insulin-like growth factor-binding protein 3 (igfbp-3) in 29 acromegalic patients and 30 health persons served as normal controls. |
1999-06-07 |
2023-08-12 |
human |
| D Somjen, K Tordjman, Y Greenman, F Kohen, G E Ouaknine, N Ster. TRH is a tonic secretagogue in growth hormone secreting but not in nonfunctioning pituitary tumors. Journal of endocrinological investigation. vol 22. issue 2. 1999-06-07. PMID:10195376. |
if endogenous trh exerts a similar continuous effect it may contribute to the disregulated gh secretion in acromegaly. |
1999-06-07 |
2023-08-12 |
human |
| U Lindbom, A L Hulting, T Tomso. Paradoxical GH response to TRH during status epilepticus in man. European journal of endocrinology. vol 140. issue 4. 1999-06-01. PMID:10097249. |
trh is not considered a gh-releasing hormone in humans during normal conditions, but a paradoxical response of gh to trh, similar to that observed during status epilepticus, has been reported in various other pathological conditions, such as acromegaly, liver cirrhosis, mental depression and hypothyroidism. |
1999-06-01 |
2023-08-12 |
Not clear |
| A Colao, P Marzullo, D Ferone, V Marinò, R Pivonello, C Di Somma, A Di Sarno, A Giaccio, G Lombard. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. Journal of endocrinological investigation. vol 22. issue 1. 1999-05-20. PMID:10090136. |
), to that of octreotide (oct) (0.3-0.6 mg/day s.c.) in 45 patients with active acromegaly (gh, 63.2+/-12.1 ng/ml, igf-i, 757+/-67.1 ng/ml). |
1999-05-20 |
2023-08-12 |
Not clear |
| M Castro Cabezas, P M Zelissen, G H Jansen, A P Van Gils, H P Koppeschaa. Acromegaly: report of two patients with an unusual presentation. The Netherlands journal of medicine. vol 54. issue 4. 1999-05-11. PMID:10218386. |
growth hormone (gh) producing tumours usually present with the clinical manifestations of acromegaly due to excessive gh secretion or symptoms resulting from mass effects of the enlarging tumour. |
1999-05-11 |
2023-08-12 |
Not clear |
| R Groote Veldman, G van den Berg, S M Pincus, M Frölich, J D Veldhuis, F Roelfsem. Increased episodic release and disorderliness of prolactin secretion in both micro- and macroprolactinomas. European journal of endocrinology. vol 140. issue 3. 1999-05-10. PMID:10216513. |
these abnormalities of secretory control are very similar to those for gh and acth identified earlier in acromegaly and cushing's disease respectively, thus suggesting mechanistic generality of pituitary tumor secretory derangements, independent of the particular hormone. |
1999-05-10 |
2023-08-12 |
Not clear |
| I Hernandez, D Soderlund, A L Espinosa-de-los-Monteros, R Ochoa, A Zarate, M Mercad. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly. Journal of neurosurgery. vol 90. issue 4. 1999-04-23. PMID:10193608. |
levels of ghbp are decreased in patients with active acromegaly, probably because of downregulation of gh receptors. |
1999-04-23 |
2023-08-12 |
Not clear |
| V J Parfitt, D Flanagan, P Wood, B A Leatherdal. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1. Clinical endocrinology. vol 49. issue 5. 1999-04-22. PMID:10197081. |
to assess the outpatient investigations, overnight urinary growth hormone (ugh) excretion, random serum gh and insulin like growth factor 1 (igf-1), and gh indices from the oral glucose tolerance test (ogtt) (fasting, nadir and mean gh), as measures of mean gh secretion in treated acromegaly, in comparison with a gh day series, which served as a gold standard. |
1999-04-22 |
2023-08-12 |
Not clear |
| C A Lissett, S R Peacey, I Laing, L Tetlow, J R Davis, S M Shale. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clinical endocrinology. vol 49. issue 5. 1999-04-22. PMID:10197082. |
the outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (gh) secreting adenoma. |
1999-04-22 |
2023-08-12 |
Not clear |
| C A Lissett, S R Peacey, I Laing, L Tetlow, J R Davis, S M Shale. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clinical endocrinology. vol 49. issue 5. 1999-04-22. PMID:10197082. |
acromegaly is associated with reduced life expectancy, while therapeutic 'cure' (defined by achievement of gh levels < 5 mu/l) is associated with normalization of life expectancy. |
1999-04-22 |
2023-08-12 |
Not clear |
| R Lanzi, M Losa, G Mignogna, A Caumo, A E Pontirol. The control on growth hormone release by free fatty acids is maintained in acromegaly. The Journal of clinical endocrinology and metabolism. vol 84. issue 4. 1999-04-21. PMID:10199760. |
the aim of this study was to examine whether such feedback is preserved in acromegaly, a condition in which alterations in other regulatory mechanisms of gh release occur. |
1999-04-21 |
2023-08-12 |
Not clear |
| R Lanzi, M Losa, G Mignogna, A Caumo, A E Pontirol. The control on growth hormone release by free fatty acids is maintained in acromegaly. The Journal of clinical endocrinology and metabolism. vol 84. issue 4. 1999-04-21. PMID:10199760. |
these data indicate that, in acromegaly, the acute reduction of circulating ffa levels results in increased gh release, whereas the increase in circulating ffa levels is accompanied by a reduced gh release. |
1999-04-21 |
2023-08-12 |
Not clear |
| R Lanzi, M Losa, G Mignogna, A Caumo, A E Pontirol. The control on growth hormone release by free fatty acids is maintained in acromegaly. The Journal of clinical endocrinology and metabolism. vol 84. issue 4. 1999-04-21. PMID:10199760. |
taken together, these findings suggest that, in acromegaly, the control of ffa on gh release is preserved. |
1999-04-21 |
2023-08-12 |
Not clear |
| T Laursen, L Lemming, J O Jørgensen, I C Klausen, J S Christianse. Different effects of continuous and intermittent patterns of growth hormone administration on lipoprotein levels in growth hormone-deficient patients. Hormone research. vol 50. issue 5. 1999-03-22. PMID:9873197. |
growth hormone (gh) administration to gh-deficient (ghd) adults increases serum lp(a) concentrations, and the levels of lp(a) and gh are correlated in patients with acromegaly. |
1999-03-22 |
2023-08-12 |
rat |
| R Attanasio, G Oppizzi, S Lodrini, D Dallabonzana, M Barausse, P Orlandi, N DaRe, R Cozz. Neurosurgery restores late GH rise after glucose-induced suppression in cured acromegalics. European journal of endocrinology. vol 140. issue 1. 1999-03-03. PMID:10037247. |
a decrease of gh levels below 2 microg/l after an oral glucose tolerance test (ogtt) is still currently accepted as the gold standard for assessing cure in surgically treated acromegaly. |
1999-03-03 |
2023-08-12 |
Not clear |